| References |
1. Crawford LJ, Anderson G, Johnston CK, Irvine AE. Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. Oncotarget. 2016 Oct 25;7(43):70481-70493. doi: 10.18632/oncotarget.12026. PubMed PMID: 27655696; PubMed Central PMCID: PMC5342567. 2. Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768. PubMed PMID: 26716651; PubMed Central PMCID: PMC4826190. 3. Giovinazzi S, Bellapu D, Morozov VM, Ishov AM. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy. Cell Cycle. 2013 Aug 15;12(16):2598-607. doi: 10.4161/cc.25591. Epub 2013 Jul 9. PubMed PMID: 23907120; PubMed Central PMCID: PMC3865049. 4. Hu K, Liao D, Wu W, Han AJ, Shi HJ, Wang F, Wang X, Zhong L, Duan T, Wu Y, Cao J, Tang J, Sang Y, Wang L, Lv X, Xu S, Zhang RH, Deng WG, Li SP, Zeng YX, Kang T. Targeting the anaphase-promoting complex/cyclosome (APC/C)- bromodomain containing 7 (BRD7) pathway for human osteosarcoma. Oncotarget. 2014 May 30;5(10):3088-100. PubMed PMID: 24840027; PubMed Central PMCID: PMC4102794. |
